A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Trial status:Recruitment Complete
Study Identifier:
GO39733
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Recruitment Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18+
Estimated Trial Date
Dec 2017 - Nov 2024
Protocol summary
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
Trial locations
Location
Status
Location
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona, United States, 85258
Status
Location
The Los Angeles Clinic
Los Angeles, California, United States, 90025
Status
Location
Stanford Cancer Center
Palo Alto, California, United States, 94304
Status
Location
UCSF Comprehensive Cancer Ctr
San Francisco, California, United States, 94158
Status
Location
University of Colorado
Aurora, Colorado, United States, 80045-2517
Status
Location
Yale University Cancer Center, Smilow Cancer Hospital; Medical Oncology
New Haven, Connecticut, United States, 06511
Status